Key facts
- · Type: Amendment first sale 2023-10-24 · Amount sold: $1.60M · Total offering: $4.10M · SEC filing
- · Type: New offering first sale 2023-10-24 · Amount sold: $1.57M · Total offering: $3M · SEC filing
- · Type: New offering first sale 2023-06-01 · Amount sold: $4K · Total offering: $4K · SEC filing
Is Kaida BioPharma Inc. a real, registered company?
Kaida BioPharma Inc. is a registered filer with the SEC (CIK 1973954) and has filed since 2023-06-14. 3 filings are on record, the latest on 2026-09-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Kaida BioPharma Inc.?
Kaida BioPharma Inc.'s filings name Craig Pierson, Stella Vnook, Richard Warburg and 1 more as its officers, directors or promoters.
How much has Kaida BioPharma Inc. raised?
Its new offerings report $1.57M sold across 2 offerings, as its own filings state.
Run the free check on Kaida BioPharma Inc. →
FORT LAUDERDALE, FLORIDA
2022
Biotechnology
3
$1.57M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-09-01 | Amendment first sale 2023-10-24 | $1.60M | $4.10M | SEC filing |
| 2026-01-21 | New offering first sale 2023-10-24 | $1.57M | $3M | details · SEC filing |
| 2023-06-14 | New offering first sale 2023-06-01 | $4K | $4K | SEC filing |
Want the whole picture on Kaida BioPharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kaida BioPharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kaida BioPharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Kaida BioPharma Inc.'s own filings with the SEC. The people those filings name are on the team page.